

Gender: Female | Birth year: 1975 | WHO: 1

Tumor: Lung - Adenocarcinoma | Lesions: Liver, Lung | Stage: IV

Summary

Clinical summary

| | | | |
|-------------------------------------|---|------------|--------------------------|
| Gender | Female | Birth year | 1975 |
| WHO | 1 | Tumor | Lung - Adenocarcinoma |
| Lesions | Liver, Lung | Stage | IV |
| Measurable disease (RECIST) | Yes | DPYD | *1_HOM (Normal function) |
| | | UGT1A1 | *1_HOM (Normal function) |
| Relevant systemic treatment history | 6/2023-1/2025 Osimertinib | | |
| Relevant other oncological history | None | | |
| Previous primary tumor | None | | |
| Relevant non-oncological history | 2023 Rheumatoid arthritis | | |
| Recent molecular results | KRAS G12C (0.3/2 copies)*, KRAS G12D (0.3/2 copies)*, NRAS: No reportable events, BRAF: No reportable events, HER2: No reportable events, MSS | | |

Recent molecular results

Hartwig WGS (22-Feb-2025)

| | |
|---|--|
| Biopsy location | Lung (purity 50%) |
| Molecular tissue of origin prediction | Lung: Non-small cell: LUAD (98%) |
| Tumor mutational load / burden | TML 160 / TMB 14 mut/Mb |
| Microsatellite (in)stability | Stable |
| HR status | Proficient (0) |
| Driver mutations | EGFR C797S, EGFR L858R, KRAS G12C, KRAS G12D |
| Amplified genes | None |
| Deleted genes | TP53 |
| Homozygously disrupted genes | None |
| Gene fusions | MET(exon13)::MET(exon15) fusion |
| Virus detection | None |
| Potential trial events, considered no high driver | None |

IHC results

| | |
|-------|-------------|
| PD-L1 | Score > 50% |
|-------|-------------|

Standard of care options considered potentially eligible

There are no standard of care treatment options for this patient

Approved treatments considered eligible

| |
|--------------------|
| Treatment |
| Not yet determined |

Trials in NL that are open and potentially eligible (3 cohorts from 3 trials)

| Trial | Cohort | Molecular | Sites | Warnings |
|---|--------------------------------------|-------------------|--|---|
| METC 04 TEDR1 | Lung cancer C797S cohort | EGFR C797S | NKI-AvL | None |
| METC 02 KAYRAS | Dose expansion - monotherapy - NSCLC | KRAS G12D | Erasmus MC | Variant(s) G12D in KRAS but subclonal likelihood of > 50% |
| EGFR-L858R-TRIAL | <i>EGFR L858R</i> | <i>EGFR L858R</i> | <i>Elisabeth-TweeSteden Ziekenhuis</i> | |

Trials matched solely on molecular event and tumor type (no clinical data used) are shown in italicized, smaller font.
1 trial filtered due to eligible local trials for the same molecular target and/or the trial is for young adult patients. See Other Trial Matching Results for filtered matches.

International trials that are open and potentially eligible (1 cohort from 1 trial)

| Trial | Cohort | Molecular | Sites |
|------------------------------------|-----------|-----------|--------------------|
| KRAS-G12C-TRIAL-DE | KRAS G12C | KRAS G12C | Germany: Stuttgart |

International trials are matched solely on molecular event and tumor type (clinical data excluded).
1 trial filtered due to trials recruiting nationally for the same molecular target. See Other Trial Matching Results for filtered matches.

Trials and cohorts that are considered ineligible (2)

| Trial | Cohort | Molecular | Ineligibility reasons |
|---|---|------------|---------------------------------------|
| METC 03 NO-SEE797ES | Dose escalation - monotherapy | EGFR C797S | C797S in EGFR in canonical transcript |
| METC 02 KAYRAS | Dose expansion - monotherapy - Colorectum | KRAS G12D | No colorectal cancer |

Resistance evidence

Resistance evidence

There are no standard of care treatment options for this patient

Molecular Details

Hartwig WGS (EXAMPLE-LUNG-01-T, 22-Feb-2025)

General

| Purity | Ploidy | TML Status | TMB Status | MS Stability | HR Status | DPYD | UGT1A1 |
|--------|--------|------------|------------|--------------|----------------|--------------------------|--------------------------|
| 50% | 2.3 | High (160) | High (14) | Stable | Proficient (0) | *1_HOM (Normal function) | *1_HOM (Normal function) |

Predicted tumor origin

| 1. Lung: Non-small cell: LUAD | |
|---|-----|
| Combined prediction score | 98% |
| This score is calculated by combining information on: | |
| (1) SNV types | 60% |
| (2) SNV genomic localisation distribution | 70% |
| (3) Driver genes and passenger characteristics | 80% |
| Other cohorts have a combined prediction of 2% or lower | |

Drivers

| Type | Driver | Driver likelihood | Trials (Locations) | Trials in Hartwig | Best evidence in External | Resistance in External |
|-----------------------------|---------------------------|-------------------|---------------------|-------------------|---------------------------|------------------------|
| Mutation (Gain of function) | EGFR C797S (1/4 copies) | | TEDR1 (NKI-AvL) | | Pre-clinical | |
| Mutation (Gain of function) | EGFR L858R (2/4 copies) | | | NCT00000006 | Approved | |
| Mutation (Gain of function) | KRAS G12C (0.3/2 copies)* | | | NCT00000009 | | |
| Mutation (Gain of function) | KRAS G12D (0.3/2 copies)* | | KAYRAS (Erasmus MC) | | | |
| Deletion | TP53 del, 0 copies | High | | | | |

The table continues on the next page

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report. Gene and variant annotations and related content are powered by Genomenon Cancer Knowledgebase (CKB).

Continued from the previous page

| Type | Driver | Driver likelihood | Trials (Locations) | Trials in Hartwig | Best evidence in External | Resistance in External |
|------|--------|-------------------|--------------------|-------------------|---------------------------|------------------------|
|------|--------|-------------------|--------------------|-------------------|---------------------------|------------------------|

| | | | | | | |
|--------------|---------------------------------|------|--|--|--|--|
| Known fusion | MET(exon13)::MET(exon15) fusion | High | | | | |
|--------------|---------------------------------|------|--|--|--|--|

* Variant has > 50% likelihood of being sub-clonal

IHC results

| | |
|-------|-------------|
| PD-L1 | Score > 50% |
|-------|-------------|

Molecular History

Molecular history

| Event | Description | Driver likelihood | 2025-02-22 Hartwig WGS |
|---|------------------------------------|-------------------|---------------------------|
| EGFR L858R (Tier I) | Mutation (Gain of function) | | VAF 0.5% |
| EGFR C797S (Tier II) | Mutation (Gain of function) | | VAF 0.25% |
| KRAS G12C (Tier III) | Mutation (Gain of function) | | VAF 0.15% |
| KRAS G12D (Tier III) | Mutation (Gain of function) | | VAF 0.15% |
| MET(exon13)::MET(exon15) fusion (Tier III) | Known fusion Gain of function | High | Detected |
| TP53 del (Tier III) | Deletion Unknown protein effect | High | Detected |
| TMB | | | 14.0 |
| MSI | | | Stable |

SOC literature efficacy evidence

Standard of care options considered potentially eligible

The following standard of care treatment(s) could be an option for this patient. For further details per study see 'SOC literature details' section in extended report.

There are no standard of care treatment options for this patient

Clinical Details

Clinical summary

| | | |
|-------------------------------------|---------------|----------------------|
| Relevant systemic treatment history | 6/2023-1/2025 | Osimertinib |
| Relevant other oncological history | None | |
| Previous primary tumor | None | |
| Relevant non-oncological history | 2023 | Rheumatoid arthritis |

Patient current details (20-Feb-2025)

| | |
|----------------------------------|-----------------------------|
| Unresolved toxicities grade => 2 | None |
| LVEF | 50% |
| Cancer-related complications | None |
| Known allergies | None |
| Recent surgeries | 01-Aug-2024 Cholecystectomy |

Tumor details (20-Feb-2025)

| | |
|---------------------|------------------------|
| Measurable disease | Yes |
| CNS lesion status | No known CNS lesions |
| Brain lesion status | No known brain lesions |

Active medication details

| Medication | Administration route | Start date | Stop date | Dosage | Frequency |
|-----------------|----------------------|-------------|-----------|----------------|------------|
| St. John's Wort | Oral | 01-Feb-2023 | | 300 MILLIGRAMS | 1 / 2 DAYS |

Blood transfusions

| Product | Date |
|----------------------|-------------|
| ERTHROCYTES_FILTERED | 20-Sep-2024 |

Molecular Evidence

On label clinical evidence

| Event | CKB Event | Level A | Level B | Level C | Level D |
|------------|------------|---|---------|---------|---|
| EGFR C797S | EGFR C797S | | | | AFATINIB <i>Lung non-small cell carcinoma (2015)</i> |
| EGFR L858R | EGFR L858R | OSIMERTINIB <i>Lung non-small cell carcinoma (2016)</i> AFATINIB <i>Lung non-small cell carcinoma (2013)</i> | | | |

Off label clinical evidence

| Event | CKB Event | Level A | Level B | Level C | Level D |
|-------|-----------|---------|---------|---------|---------|
| None | | | | | |

Efficacy evidence description

| | | | |
|--------------|----------------|-------------------------------|---|
| EGFR L858R | | | |
| OSIMERTINIB: | Level A (2016) | Lung non-small cell carcinoma | Osimertinib is effective in patients with EGFR L858R mutations |
| AFATINIB: | Level A (2013) | Lung non-small cell carcinoma | Afatinib is effective in patients with EGFR L858R mutations |
| EGFR C797S | | | |
| AFATINIB: | Level D (2015) | Lung non-small cell carcinoma | In a case-report, afatinib was effective against EGFR L858R/C797S positive lung cancer. |

Treatment ranking

| Treatment | Events | Score |
|-------------|--------------------------|-------|
| AFATINIB | EGFR L858R EGFR C797S | 2,150 |
| OSIMERTINIB | EGFR L858R | 1,900 |

Other Trial Matching Results

Trials in NL that are open and potentially eligible (1 cohort from 1 trial)

| Trial | Cohort | Molecular | Sites | Warnings |
|----------------------------------|------------|------------|--|----------|
| EGFR-L858R-TRIAL | EGFR L858R | EGFR L858R | <i>Elisabeth-TweeSteden Ziekenhuis</i> | |

Trials matched solely on molecular event and tumor type (no clinical data used) are shown in italicized, smaller font.
1 trial filtered due to eligible local trials for the same molecular target and/or the trial is for young adult patients. See Other Trial Matching Results for filtered matches.

International trials that are open and potentially eligible (1 cohort from 1 trial)

| Trial | Cohort | Molecular | Sites |
|------------------------------------|-----------|-----------|--------------------|
| KRAS-G12C-TRIAL-DE | KRAS G12C | KRAS G12C | Germany: Stuttgart |

International trials are matched solely on molecular event and tumor type (clinical data excluded).
1 trial filtered due to trials recruiting nationally for the same molecular target. See Other Trial Matching Results for filtered matches.

Filtered trials potentially eligible based on molecular results which are potentially recruiting (2)

| Trial | Cohort | Molecular | Sites |
|----------------------------------|------------|------------|---------------------------------|
| EGFR-C797S-TRIAL | EGFR C797S | EGFR C797S | Elisabeth-TweeSteden Ziekenhuis |
| EGFR-BE | EGFR L858R | EGFR L858R | Belgium: Brussels |